Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Coherus Biosciences (CHRS)
NASDAQ:CHRS
CHRS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.65
Previous CloseN/A
Volume565.36K
Average Volume (3M)2.01M
Market Cap
$129.80M
Enterprise Value$321.61M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.31
Next Earnings
Feb 27, 2025EPS Estimate
-0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding115,890,180
10 Day Avg. Volume1,165,810
30 Day Avg. Volume2,009,281
Standard Deviation0.19
R-Squared0.05
Alpha-0.04
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.42
Price to Cash Flow (P/CF)-0.50
P/FCF Ratio0.00
Enterprise Value/Market Cap2.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.40
Enterprise Value/Ebitda-2.96
Forecast
1Y Price Target
$7.00Price Target Upside536.36% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
---
Coherus Biosciences News
PremiumCompany Announcements
Coherus Biosciences Announces UDENYCA Divestiture and Revenue Outlook
PremiumCompany Announcements
Coherus Biosciences Announces Board Member Resignation
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial SuccessThe company reported positive final data from a Phase 2 study in patients with metastatic hepatocellular carcinoma, showcasing the efficacy of their triplet therapy.
Debt ReductionCoherus scored a big win with its announced divestiture of the Udenyca franchise for ~$483.4M upfront cash payment, giving the company the ability to largely eliminate debt from its balance sheet which has been the key overhang on shares.
Guideline UpdateLoqtorzi is establishing its commercial value with the recent update of the National Comprehensive Cancer Network (NCCN) guidelines in which Loqtorzi is now the only preferred regimen in combination with chemo for the treatment of advanced nasopharyngeal carcinoma in the first line setting and beyond.
Bears Say
Lowered Revenue EstimatesCoherus is lowering its 4Q24 and 2025/2026 Udenyca estimates.
Regulatory And Clinical RisksRisks include regulatory and clinical challenges, as some products are not approved, and competition in the market could impact pricing.
Supply Chain DisruptionThe major focus of the call was the CMO supply chain disruption, which management announced will last approximately three weeks longer than expected.
---
Ownership Overview
1.22% Insiders
15.46% Mutual Funds
17.84% Other Institutional Investors
55.40% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CHRS FAQ
What was Coherus Biosciences’s price range in the past 12 months?
Coherus Biosciences lowest stock price was $0.66 and its highest was $2.65 in the past 12 months.
What is Coherus Biosciences’s market cap?
Coherus Biosciences’s market cap is $129.80M.
When is Coherus Biosciences’s upcoming earnings report date?
Coherus Biosciences’s upcoming earnings report date is Feb 27, 2025 which is in 6 days.
How were Coherus Biosciences’s earnings last quarter?
Coherus Biosciences released its earnings results on Nov 06, 2024. The company reported -$0.09 earnings per share for the quarter, beating the consensus estimate of -$0.163 by $0.073.
Is Coherus Biosciences overvalued?
According to Wall Street analysts Coherus Biosciences’s price is currently Undervalued.
Does Coherus Biosciences pay dividends?
Coherus Biosciences does not currently pay dividends.
What is Coherus Biosciences’s EPS estimate?
Coherus Biosciences’s EPS estimate is -0.31.
How many shares outstanding does Coherus Biosciences have?
Coherus Biosciences has 115,890,180 shares outstanding.
What happened to Coherus Biosciences’s price movement after its last earnings report?
Coherus Biosciences reported an EPS of -$0.09 in its last earnings report, beating expectations of -$0.163. Following the earnings report the stock price went up 13.889%.
Which hedge fund is a major shareholder of Coherus Biosciences?
Currently, no hedge funds are holding shares in CHRS
---
Coherus Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (536.36% Upside)
$7.00 (536.36% Upside)
Blogger Sentiment
Bullish
CHRS Sentiment 100%
Sector Average 70%
Sector Average 70%
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 7.1%
Last 30 Days ▲ 7.1%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.14%
12-Months-Change
Fundamentals
Return on Equity
0.51%
Trailing 12-Months
Asset Growth
-13.50%
Trailing 12-Months
Company Description
Coherus Biosciences
Coherus BioSciences, Inc. is a commercial-stage clinical biologics platform company, which engages in the development and commercialization of biosimilar therapeutics. Its clinical products include pegfilgrastim biosimilar, adalimumab biosimilar, etanercept biosimilar, ranibizumab biosimilar, and aflibercept biosimilar. The company was founded by Dennis M. Lanfear, Stuart E. Builder, Dr. Alan Herman, Doug Farrar and Steve Glover in September 2010 and is headquartered in Redwood City, CA.
---
CHRS Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted significant revenue growth for UDENYCA and LOQTORZI, improved financial performance, and promising pipeline advancements. However, challenges included a supply interruption affecting UDENYCA and a net loss, though financial losses were reduced compared to the previous year.Read More>---
CHRS Stock 12 Month Forecast
Average Price Target
$7.00
▲(536.36% Upside)
Technical Analysis
Agenus
―
Fate Therapeutics
―
Heron Therapeutics
―
Blueprint Medicines
―
Adaptimmune Therapeutics
―
Best Analysts Covering CHRS
1 Year
1 Year Success Rate
3/25 ratings generated profit
1 Year Average Return
-32.20%
reiterated a buy rating 26 days ago
Copying Balaji Prasad's trades and holding each position for 1 Year would result in 12.00% of your transactions generating a profit, with an average return of -32.20% per trade.
---